NCT07488507 Diagnostic Value and Safety of Combined Biopsy for Mediastinal Metastasis of Lung Cancer
| NCT ID | NCT07488507 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Third Military Medical University |
| Condition | Mediastinal Metastases of Lung Cancer |
| Study Type | INTERVENTIONAL |
| Enrollment | 240 participants |
| Start Date | 2026-03-20 |
| Primary Completion | 2030-03-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 240 participants in total. It began in 2026-03-20 with a primary completion date of 2030-03-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The study is aimed o evaluate the diagnostic performance and treatment guidance of endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) combined with transbronchial mediastinal cryobiopsy (EBUS-TBMCB) in patients with mediastinal metastases of lung cancer.
Eligibility Criteria
Inclusion Criteria: 1. Aged ≥18 years; 2. Presence of at least one mediastinal lesion (short-axis diameter ≥10 mm) confirmed by thin-slice chest CT; 3. Patients who have not undergone prior mediastinal biopsy and require further mediastinal biopsy to confirm etiology or pathological subtype, meeting at least one of the following criterias: (1) suspected lung cancer diagnosed by two senior physicians; (2) confirmed lung cancer (requiring mediastinal staging); (3) recurrent lung cancer; 4.Patients must have completed all required preoperative laboratory tests and necessary examinations (e.g., cardiac ultrasound, CTA) to rule out contraindications; 5. Patients are informed and capable of providing written informed consent. Exclusion Criteria: 1. Presence of severe cardiopulmonary disease, coagulation disorders, massive hemoptysis, poor tolerance to anesthesia, or other contraindications related to bronchoscopy; 2. Intraoperative endobronchial ultrasound exploration of the lesion failed to detect the target lesion despite \> 20 minutes of attempts; 3. Lesions identified as abscesses or cysts; 4. Presence of mental illness, severe neurosis, or other conditions that preclude the provision of informed consent; 5. Patients who have participated in other clinical trials within 3 months; 6. Any other conditions considered to be inappropriate to be involved in this trial.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07488507 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Mediastinal Metastases of Lung Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07488507 currently recruiting?
Yes, NCT07488507 is actively recruiting participants. Contact the research team at 18885230175@163.com for enrollment information.
Where is the NCT07488507 trial being conducted?
This trial is being conducted at Chongqing, China.
Who is sponsoring the NCT07488507 clinical trial?
NCT07488507 is sponsored by Third Military Medical University. The trial plans to enroll 240 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.